Description

Defensin HNP-1 human TFA is a Human neutrophil peptides (HNPs), involved in endothelial cell dysfunction at the time of early atherosclerotic development. Defensin HNP-1 human TFA exhibits broad antimicrobial and anti-leishmanial activities[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C160H227F15N44O48S6—-[1]Dabirian S, et, al. Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate. PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2491.|[2]Higazi M, et, al. Opposing effects of HNP1 (α-defensin-1) on plasma cholesterol and atherogenesis. PLoS One. 2020 Apr 17;15(4):e0231582.|[3]Higazi M, et al. Opposing effects of HNP1 (α-defensin-1) on plasma cholesterol and atherogenesis. PLoS One. 2020 Apr 17;15(4):e0231582. —-4012.15–98.16–O=C(N[C@H]1CC2=CNC3=CC=CC=C23)[C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC(CNC([C@H](CCC(N)=O)NC([C@H](CC4=CC=C(O)C=C4)NC([C@]([H])([C@H](CC)C)NC([C@]5(NC([C@]([H])([C@@H](C)O)NC(CNC([C@H](CC6=CC=C(O)C=C6)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(O)=O)NC(CNC([C@H](C)NC([C@]([H])([C@H](CC)C)NC([C@@]7(CSSC[C@]([H])(NC([C@H](CC8=CC=CC=C8)NC([C@H](C)NC1=O)=O)=O)C(N[C@H](C(O)=O)CSSC[C@H](NC([C@H](C)N)=O)C(N[C@@H](CC9=CC=C(O)C=C9)C(N[C@]([H])(C(N[C@@H](CCCNC(N)=N)C(N[C@@]([H])([C@H](CC)C)C(N[C@]([H])(C(N[C@@H](C)C(N7)=O)=O)CCC)=O)=O)=O)CSSC5)=O)=O)=O)[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[H])=O)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F–Infection; Cardiovascular Disease–H2O–Bacterial;Parasite–Leishmania–Anti-infection–Peptides